UK markets closed
NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,284.54 +83.27 (+0.48%) CRUDE OIL
82.51 -0.30 (-0.36%) GOLD FUTURES
2,339.60 +1.20 (+0.05%) DOW
37,995.47 -465.45 (-1.21%) Bitcoin GBP
51,233.17 -385.93 (-0.75%)
Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 12:37PM EDT. Market open.
| Previous close | 127.00 |
| Open | 129.69 |
| Bid | 130.02 x 900 |
| Ask | 130.05 x 900 |
| Day's range | 128.76 - 132.79 |
| 52-week range | 99.14 - 133.10 |
| Volume | |
| Avg. volume | 8,364,783 |
| Market cap | 329.384B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 928.83 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (2.43%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Business Wire
Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
- Business Wire
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
RAHWAY, N.J., April 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%).
- Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
© 2024 Yahoo. All rights reserved.